Maybe the FDA are just struggling to find something to object to.
Maybe the FDA's normal business model isn't equipped to handle a gamechanger/blockbuster drug efficiently.
Maybe PAR have done such a great job with the stack of clinical data that it is taking the FDA a painfully long time to get through it.
They wouldn't take this long to find a fatal flaw in the data, although they could have spent an inordinate amount of time looking for one.
I hate waking up every morning to no news, but every day of no news means they still haven't found a reason to say no.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.030(7.14%) |
Mkt cap ! $170.8M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 46.0¢ | 42.0¢ | $295.3K | 680.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 17489 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 7907 | 1 |
View Market Depth
| Last trade - 14.39pm 15/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |